Tumor necrosis factor (TNF) inhibitors are increasingly applied during pregnancy without clear knowledge of the impact on placenta and fetus. In a recent paper published in Clinical Pharmacology and Therapeutics, researchers from the Departments of Pharmacology and Toxicology, Obstetrics and Gynecology, and Health Evidence, in collaboration with Sanquin Diagnostic Services, investigated the placental handling of the TNF inhibitors infliximab and etanercept.
In their study, Gaby Eliesen and colleagues combined clinical observations with preclinical studies. In clinical work, the placental drug disposition was studied in women with autoimmune diseases who were treated with TNF inhibitors throughout pregnancy. In the preclinical studies, fetal and maternal circulations of term human, TNF-inhibitor-naïve, placentas were re-established immediately after birth. In a controlled laboratory setting, it was then studied how the placenta handled the drugs in the initial six hours after first exposure ex vivo.
A main finding of the study was that infliximab concentrations in placenta tissue reached markedly higher levels than etanercept. This was observed both in the clinical cases as well as in the ex vivo perfused placentas. The authors indicate that the difference in placental tissue exposure may be of clinical relevance and warrants further investigation. More specifically, future studies should look into the occurrence of placental TNF inhibition and possible consequences thereof.
Related news items
Joint research in regional hospitals New research projects from promotion fund22 November 2022
Four research projects have been honored in the promotion fund of the Radboudumc and four regional hospitals. The research projects, which are a collaboration between CWZ, Jeroen Bosch Hospital, Rijnstate, Sint Maartenskliniek and the Radboudumc will receive a contribution of 240,000 euros.read more